Pain Medicine News

Part 3 of this 3-part podcast series reviews FDA recommendations for translating data from in vitro, pharmacokinetic, clinical abuse potential, and postmarket studies into abuse-deterrent product labeling. You can read more about this topic here.

Part 2 of this 3-part podcast series focuses on premarket and postmarket studies that are required for demonstrating the potential to reduce abuse. You can read more about this topic here.You can read more about this topic here.

Dr. Nagel, author of the "Postherpetic Neuralgia: New Perspectives on Pathogenesis and Treatment" educational review, on the emerging role of antiviral therapy for postherpetic neuralgia.

Part 1 of this 3-part podcast series reviews various abuse-deterrent technologies intended to provide efficacious opioid analgesia while reducing the risk for potential abuse and misuse. You can read more about this topic here.

Pain Medicine News' editorial board member Andrea Trescot, MD, speaks with editor Donald Pizzi about her new educational review, "Genetic Testing in Pain Medicine," published in the April issue.

Pain Medicine News’ editor, Donald Pizzi talks with David Craig, PharmD, BCPS, a clinical pharmacist specialist and director of the Pain and Palliative Care Specialty Residency at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida about the FDA’s draft guidance for manufacturers developing abuse-deterrent opioids.

Physicians for Responsible Opioid Prescribing president Andrew Kolodny speaks with editor Donald Pizzi about the group's petition to the FDA to change opioid labeling in the October podcast. 

Editor Donald Pizzi discusses the Senate investigation into opioid manufacturers and professional associations with incoming AAPM president Lynn Webster in the July podcast.

In the June 2012 Pain Medicine News podcast, editor Donald M. Pizzi and editorial board member and ASIPP past president Andrea Trescot, MD, discuss the case of Richard Kaul, an interventional pain physician who had his medical license suspended after the New Jersey attorney general accused him of performing invasive spinal surgery without the proper training.

Editor Donald Pizzi and editorial board member Charles Argoff, MD, detail a study showing high rates of tenfold medication errors in pediatric patients; the decision by a struggling pain clinic to reinvent itself; and the controversies surrounding the Rockefeller Bill.

Editor Donald Pizzi and editorial board member Charles Argoff, MD, detail the coverage battle between interventional pain physicians and insurance companies; chronic anger in chronic pain patients; and the need for better labeling for OTC painkillers like acetaminophen.  

Pain Medicine News' editor Donald Pizzi and editorial board member Charles Argoff, MD,  discuss the use of opioids to treat cancer pain, the efforts to implement a prescription drug monitoring program in Florida, and a new study showing that 80% of the world has little or no access to pain drugs.

This month, Pain Medicine News' editor Donald Pizzi and editorial board member Charles Argoff, MD, discuss three of the more thought-provoking stories from the May issue of Pain Medicine News. They include stories on the high rate of opioid abuse among former National Football League players; the murky ethics and potential effectiveness of proposed mandatory urine drug testing for opioid patients in the state of Florida; and a call for improved pain training for psychiatrists.

In this month's podcast, Pain Medicine News' editor Donald Pizzi and editorial board member Charles Argoff, MD, review several articles from the March issue. They discuss the effectiveness and efficacy of opioid agreements, the results of a study showing overweight fibromyalgia patients have higher pain sensitivity and whether the FDA mishandled the Colcrys drug approval.

In this month’s podcast, Pain Medicine News' editor Donald Pizzi and editorial board member Charles Argoff, MD, review several articles from the February issue. They discuss whether physicians should be concerned with the spike in gout prevalence in the United States, whether too many infant pain scales exist and whether the ICHD-II criteria for new daily persistent headache should be broadened to include patients with migrainous features.

Pain Medicine News' editor Donald Pizzi and editorial board member Charles Argoff, MD, review highlights from the January issue.

Pain Medicine News' contributing editor, David Bronstein, reviews the FDA’s recent recommendation to pull propoxyphene off the market with Sidney M. Wolfe, MD, director of Public Citizen' s Health Research Group. Dr. Wolfe first called for the painkiller to be banned more than 30 years ago.

Cervical dystonia (CD) is characterized by involuntary muscle contractions that cause abnormal movements and posturing of the head and neck as well as significant pain. It is the most common form of focal dystonia, with an estimated prevalence of 90,000 in the United States.Supported and Approved by Solstice Neurosciences

Central sensitization plays a key role in the processing and maintenance of some chronic pain. Dr. Argoff, Professor of Neurology at Albany Medical College and Director of the Comprehensive Pain Program at Albany Medical Center, discusses this important pathophysiologic mechanism of pain.Supported and approved by Eli Lilly and Company

Dr. David Fishbain, Professor of Psychiatry and Adjunct Professor of Neurological Surgery and Anesthesiology at the University of Miami Miller School of Medicine in Miami, discusses the complex relationship between diabetic peripheral neuropathic pain (DPNP) and sleep.Supported and approved by Eli Lilly and Company